Mouse CD200 Protein (C-His-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P-) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of Mouse CD200 protein exceeds 90%.
Cat #
Size
Price
Quantity
815603
25 ug
$245
815604
100 ug
$595
Product Details
Application
ELISA, BLI
Format
Liquid, Biotinylated
Expression Host
CHO
Target Name
CD200, MOX1, MOX2, MRC, OX-2, My033
Species
Mouse
Sources
Recombinant Mouse CD200 (Gln31-Gly232) with C-terminus His-Avi-tag is expressed in CHO cell. This protein was site-specifically labeled with Biotin by BirA ligase.
accession number
O54901
Molecular Weight
The protein has a predicted molecular weight of 26.1 kDa. Under DTT-reducing conditions, it migrates at approximately 45 kDa on SDS-PAGE.
Affinity Tag
C-His-Avi
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
CD200 (OX-2) is a cell surface glycoprotein that regulates immune responses through its receptor, CD200R, mainly expressed on myeloid cells. It plays a crucial role in suppressing alloimmune and autoimmune responses, contributing to immune privilege in various tissues. CD200-CD200R signaling is essential in regulating anti-tumor immunity, with overexpression linked to malignancies like chronic lymphocytic leukemia (CLL) and cancer stem cells. Additionally, CD200 signaling is involved in the central nervous system, particularly in diseases like Parkinson's, where it affects microglia activation. Elevated CD200 expression is associated with reduced transplant rejection, autoimmunity, and allergic diseases, but may also promote tumor cell survival. While it helps prevent graft rejection and autoimmune diseases, high CD200 levels in cancers have been linked to poor prognosis. This dual role underscores the complexity of CD200 in immune regulation and its potential as both a therapeutic target and a biomarker.
Mouse CD200 Protein (C-His-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P-) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of Mouse CD200 protein exceeds 90%.
